Detalles de la búsqueda
1.
Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
Diabetes Obes Metab
; 21(4): 1027-1036, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30614616
2.
Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.
Diabetes Obes Metab
; 21(6): 1474-1482, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30830724
3.
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
Am Heart J
; 206: 11-23, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30290289
4.
Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.
Diabetes Obes Metab
; 20(6): 1453-1460, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29419917
5.
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
Diabetes Obes Metab
; 20(3): 520-529, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28857451
6.
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Diabetes Obes Metab
; 20(5): 1111-1120, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29266675
7.
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
Diabetes Obes Metab
; 20(3): 530-540, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28921862
8.
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
Diabetes Obes Metab
; 19(5): 721-728, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28116776
9.
Effects of Extended-Release Niacin and Extended-Release Niacin/Laropiprant on the Pharmacokinetics of Simvastatin in Healthy Subjects.
Am J Ther
; 22(5): 367-76, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-24832384
10.
Crystal structure of the human spastin AAA domain.
J Struct Biol
; 179(2): 133-7, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22446388
11.
Recognition of C-terminal amino acids in tubulin by pore loops in Spastin is important for microtubule severing.
J Cell Biol
; 176(7): 995-1005, 2007 Mar 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-17389232
12.
Possible regulation of microtubules through destabilization of tubulin.
Trends Cell Biol
; 15(11): 571-3, 2005 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-16202601
13.
Linking axonal degeneration to microtubule remodeling by Spastin-mediated microtubule severing.
J Cell Biol
; 168(4): 599-606, 2005 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-15716377
14.
Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Curr Med Res Opin
; 35(8): 1335-1343, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30760125
15.
Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study.
Diabetes Ther
; 9(1): 193-207, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29282633
16.
Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study.
Diabetes Ther
; 9(1): 253-268, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29313282
17.
Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study.
Diabetes Ther
; 9(1): 49-66, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29159457
18.
A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Curr Med Res Opin
; 33(10): 1861-1868, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28548024
19.
Cholesterol and steroid synthesizing smooth endoplasmic reticulum of adrenocortical cells contains high levels of proteins associated with the translocation channel.
Endocrinology
; 146(10): 4234-49, 2005 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-15947003
20.
Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers.
J Clin Pharmacol
; 54(7): 765-75, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24615657